| Symbol | Name | Last Close | Mkt Cap | DailyStocks' Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
|
Vote Now! Tuesday’s Close |
|---|---|---|---|---|---|
| TEVA | Teva Pharmaceutical Industries Limited | $23.43 | $23.86B | N/A |
Teva Pharmaceutical Industries Ltd (TEVA) CEO Kare Schultz on Q3 2020 Results - Earnings Call Transcript
https://seekingalpha.com/article/4385504-teva-pharmaceutical-industries-ltd-teva-ceo-kare-schultz-on-q3-2020-results-earnings-call?source=feed_tag_israel
Nov 05, 2020 - Teva Pharmaceutical Industries Ltd (NYSE:TEVA) Q3 2020 Earnings Conference Call November 05, 2020, 08:00 ET Company Participants Kevin Mannix - SVP, IR Kare Schultz - President, CEO & Director Eli Kalif - EVP & CFO Brendan O'Grady - EVP, North America Commercial Conference Call Participants Gregory Gilbert - Truist Securities Umer Raffat - Evercore ISI Aaron Gal - Sanford C.
0
Appeals court revives $235M Glaxo verdict against Teva
https://seekingalpha.com/news/3619598-appeals-court-revives-235m-glaxo-verdict-against-teva?source=feed_sector_healthcare
Oct 02, 2020 -
0
AbbVie Elezanumab Gets FDA's Fast Track and Orphan Drug Tags
http://www.zacks.com/stock/news/1068692/abbvie-elezanumab-gets-fdas-fast-track-and-orphan-drug-tags?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-1068692
Sep 29, 2020 - AbbVie's (ABBV) elezanumab is presently being evaluated in a phase II study for spinal cord injury.
0
3 Top Stocks You Can Buy and Hold for the Next Decade
https://www.fool.com/investing/2020/09/19/3-top-stocks-you-can-buy-and-hold-for-the-next-dec/?source=iedfolrf0000001
Sep 19, 2020 - Companies that are built to last are worth considering for your longer-term money, even amid a crisis.
0
Satsuma Plunges on Disappointing Data on Migraine Treatment
http://www.zacks.com/stock/news/1057087/satsuma-plunges-on-disappointing-data-on-migraine-treatment?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-1057087
Sep 11, 2020 - Satsuma (STSA) tanks as late-stage study of STS101 (dihydroergotamine [DHE] nasal) powder as an acute treatment for migraine disappoints.
0
Teva Charged In Criminal Antitrust Investigation: What It Means
https://seekingalpha.com/article/4372214-teva-charged-in-criminal-antitrust-investigation-what-means?source=feed_tag_israel
Sep 02, 2020 - One week ago, the DOJ charged Teva for overcharging customers in an alleged price-fixing conspiracy. In this article, I will take a closer look at what this lawsuit means for Teva.
0
Teva launches Rituxan biosimilar in U.S.
https://seekingalpha.com/news/3568193-teva-launches-rituxan-biosimilar-in-u-s?source=feed_sector_healthcare
May 04, 2020 - Teva Pharmaceutical Industries (NYSE:TEVA) and collaboration partner Celltrion Healthcare announce the commercial availability of Truxima (rituximab-abbs), a biosimilar to Roche's (OTCQX:RHHBY) Rituxa
0
Teva Pharmaceutical Industries Ltd. (TEVA) Gains As Market Dips: What You Should Know
http://www.zacks.com/stock/news/897134/teva-pharmaceutical-industries-ltd-teva-gains-as-market-dips-what-you-should-know?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v1-897134
Apr 28, 2020 - In the latest trading session, Teva Pharmaceutical Industries Ltd. (TEVA) closed at $10.84, marking a +1.12% move from the previous day.
0
Eagle Pharma and Teva prevail in Bendeka patent challenge
https://seekingalpha.com/news/3565267-eagle-pharma-and-teva-prevail-in-bendeka-patent-challenge?source=feed_sector_healthcare
Apr 28, 2020 - Eagle Pharmaceuticals (NASDAQ:EGRX) and licensee Teva Pharmaceutical Industries (NYSE:TEVA) announce a favorable outcome in a patent dispute from would-be generic competitors to blood cancer med Bende
0
Teva launches Ajovy autoinjector in U.S.
https://seekingalpha.com/news/3564611-teva-launches-ajovy-autoinjector-in-u-s?source=feed_sector_healthcare
Apr 27, 2020 - Teva Pharmaceutical Industries (NYSE:TEVA) announces the availability of the autoinjector device for migraine med Ajovy (fremanezumab-vfrm) at a wholesale acquisition cost (WAC) of $603.20.The
0